Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
2.
Psychooncology ; 30(11): 1894-1901, 2021 11.
Article in English | MEDLINE | ID: mdl-34197018

ABSTRACT

OBJECTIVE: Clinical guidelines recommend psychological screening in cancer patients. However, most scales cover many items and hamper detection. In addition, patients are generally referred from routine consultations. The specific objective of the present study was to develop and validate a tool, Anxiety, Depression, Coping (ADAF), to screen for anxiety and depression and assess coping in cancer patients. METHODS: Cross-sectional, multicenter study performed in the medical and radiotherapy-oncology services of five hospitals in Madrid and coordinated by the Medical Oncology Service of Hospital Clínico San Carlos (CEIC nº19/265-E). To determine psychometric properties, the ADAF screening questionnaire ADAF was administered. ADAF includes five items (1 related to anxiety symptoms, 2 related to depressive symptoms, 1 for helplessness coping, and 1 for avoidance coping). Hospital Anxiety and Depression Scale and Mini-Mental Adjustment to Cancer scale were used as the gold standards. Intraclass correlation coefficients were calculated and receiver operating characteristic (ROC) curves constructed. A p value of <0.05 was considered significant. RESULTS: A total of 186 patients completed the evaluation. The correlation coefficients were significant for all dimensions (anxiety, depression, helplessness coping, and avoidance coping) (p < 0.001). The statistical analysis of the ROC curves suggested that the cut-off point for screening was >2 points (3 in the case of depression), with a sensitivity and specificity between 62% and 90%, and an area under the curve above 0.8 for the first 4 items. CONCLUSIONS: ADAF screening has adequate reliability and good sensitivity and specificity. This instrument is useful and can be easily applied to identify emotional and coping problems in cancer patients.


Subject(s)
Depression , Neoplasms , Adaptation, Psychological , Anxiety/diagnosis , Anxiety/psychology , Cross-Sectional Studies , Depression/diagnosis , Depression/psychology , Early Detection of Cancer , Humans , Neoplasms/psychology , Psychiatric Status Rating Scales , Psychometrics/methods , Reproducibility of Results , Surveys and Questionnaires
3.
J Oncol Pharm Pract ; 24(7): 511-516, 2018 Oct.
Article in English | MEDLINE | ID: mdl-28639467

ABSTRACT

Purpose Ethanol as an excipient is used to enhance the solubility of gemcitabine, but, sometimes, the dose of ethanol a patient may be given is much higher than the dose considered to be toxic. We aimed to assess ethanol-related symptoms and signs in patients receiving two formulations of gemcitabine, with and without ethanol. Methods A randomized double blind cross-over study was conducted. All patients being treated with gemcitabine received two consecutive doses of the drug, one diluted from a concentrate for solution for infusion (CSI) containing ethanol and the other from a lyophilized powder, without ethanol, which was used as control group. After each administration, patients were surveyed in order to assess the appearance of any alcohol consumption symptoms (dizziness, difficulty speaking, unsteady walking, impaired balance, mood swings and slower reactions). Widmark formula and the amount of alcohol measured on the breath (breathalyzer) were used to estimate blood alcohol concentration. Results Twenty-four patients received both formulations and were included in the analysis. Mean administered ethanol dose when prepared from CSI was 15.81 ± 2.25 g (mean ± SD). When using CSI gemcitabine, estimated blood ethanol concentration was 0.033 g/dl according to Widmark formula and 0.02 g/dl according to breathalyzer results. Although overall incidence of symptoms was higher in the study group, the difference was not statistically significant (33% vs. 25%; p = 0.53). Conclusions These findings prove there is no difference in the onset of ethanol related symptoms when using CSI instead of lyophilized powder on the reconstitution of gemcitabine.


Subject(s)
Blood Alcohol Content , Deoxycytidine/analogs & derivatives , Ethanol/administration & dosage , Aged , Breath Tests , Cross-Over Studies , Deoxycytidine/administration & dosage , Double-Blind Method , Ethanol/adverse effects , Ethanol/blood , Female , Humans , Incidence , Male , Middle Aged , Pharmaceutical Solutions , Gemcitabine
4.
Int J Clin Pharm ; 38(4): 793-6, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27164956

ABSTRACT

Background The combination of cisplatin or carboplatin with vinorelbine is one of the standard regimens in non-small-cell lung cancer. Some studies have shown that the hemogram on day-8 could be avoided in patients with cisplatin. However, carboplatin had not been studied and is considered to be more myelotoxic than cisplatin. Objective To quantify the incidence of thrombocytopenia, anemia, neutropenia and impaired liver and renal tests on day 8 in patients receiving a doublet protocol including a platinum and vinorelbine. Method The incidence of blood test abnormalities has been quantified in all patients who had received at least one course of cisplatin or carboplatin plus vinorelbine from January 14-December 14. Results Eighty-nine patients and 314 courses on day-8 were evaluated. Moderate or severe hematological toxicity was observed in 5.7 % courses. Dose was skipped in 1.3 % courses related to neutropenia. Renal and liver impairment were not shown. Delayed and reduced doses and early discontinued treatment on day-8 were not caused by blood test abnormalities. Conclusions Blood tests might be spared on day-8 depending on the individual characteristics, above all in patients with carboplatin.


Subject(s)
Anemia/epidemiology , Carboplatin/adverse effects , Cisplatin/adverse effects , Hematologic Tests , Neutropenia/epidemiology , Thrombocytopenia/epidemiology , Vinblastine/analogs & derivatives , Anemia/chemically induced , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carboplatin/therapeutic use , Cisplatin/therapeutic use , Female , Humans , Kidney Function Tests , Liver Function Tests , Male , Middle Aged , Neoplasms/blood , Neoplasms/drug therapy , Neutropenia/chemically induced , Thrombocytopenia/chemically induced , Time Factors , Vinblastine/adverse effects , Vinblastine/therapeutic use , Vinorelbine
5.
Med. mil ; 56(2): 83-84, abr.-jun. 2000. ilus
Article in Es | IBECS | ID: ibc-37455

ABSTRACT

El diagnóstico de los tumores que debutan con metástasis óseas supone un problema frecuente. La estrategia diagnóstica debe dirigirse hacia las neoplasias más frecuentes y hacia aquellas en las que el tratamiento pueda obtener resultado. El estudio del tubo digestivo en ausencia de síntomas, normalmente queda excluido de esta búsqueda. Presentamos un paciente joven con metástasis óseas en múltiples localizaciones, sin otras manifestaciones clínicas acompañantes, en el que se detectó la presencia de un cáncer gástrico como origen de las mismas (AU)


Subject(s)
Adult , Male , Humans , Stomach Neoplasms/complications , Bone Neoplasms/secondary , Neoplasm Metastasis/pathology , Stomach Neoplasms/pathology , Neoplasms, Unknown Primary/complications
SELECTION OF CITATIONS
SEARCH DETAIL
...